The Ventricular Tachycardia drugs in development market research report provides comprehensive information on the therapeutics under development for Ventricular Tachycardia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Ventricular Tachycardia. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Ventricular Tachycardia and features dormant and discontinued products.

GlobalData tracks 11 drugs in development for Ventricular Tachycardia by ten companies/universities/institutes. The top development phase for Ventricular Tachycardia is preclinical with four drugs in that stage. The Ventricular Tachycardia pipeline has 11 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Ventricular Tachycardia pipeline products market are: ARMGO Pharma, Cardurion Pharmaceuticals and GEXVal.

The key targets in the Ventricular Tachycardia pipeline products market include Beta 1 Adrenergic Receptor (Beta 1 Adrenoreceptor or ADRB1), Calcium Channel, and Calcium/Calmodulin Dependent Protein Kinase Type II (CAMK2 or EC 2.7.11.17).

The key mechanisms of action in the Ventricular Tachycardia pipeline product include Beta 1 Adrenergic Receptor (Beta 1 Adrenoreceptor or ADRB1) Antagonist with three drugs in Filing rejected/Withdrawn. The Ventricular Tachycardia pipeline products include three routes of administration with the top ROA being Oral and two key molecule types in the Ventricular Tachycardia pipeline products market including Small Molecule, and Gene Therapy.

Ventricular Tachycardia overview

Ventricular tachycardia is a very fast heart rhythm that begins in the ventricles. Symptoms of ventricular tachycardia include dizziness, fainting, fatigue, chest pain, and shortness of breath. Causes include cardiomyopathy, ischemic heart disease, and heart failure. Risk factors include age, family history, and medical history. Treatment includes antiarrhythmic medication.

For a complete picture of Ventricular Tachycardia’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.